A Study of Ruxolitinib in Pancreatic Cancer Patients

PHASE3TerminatedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

October 31, 2016

Conditions
Pancreatic Cancer
Interventions
DRUG

Ruxolitinib

5 mg tablets to be administered by mouth twice daily (BID)

DRUG

Placebo

5 mg matching placebo tablets to be administered by mouth twice daily (BID)

DRUG

Capecitabine

150 mg or 500 mg tablets to be administered by mouth twice daily (BID)

Trial Locations (95)

Unknown

Huntsville

Fayetteville

Beverly Hills

La Jolla

Aurora

Denver

Washington D.C.

Fort Myers

St. Petersburg

Athens

Atlanta

Macon

Thomasville

Harvey

Indianapolis

Kansas City

Louisville

Baltimore

Boston

Farmington Hills

Kalamazoo

Lansing

Minneapolis

Saint Louis Park

Bolivar

Basking Ridge

Cherry Hill

Voorhees Township

Commack

Fresh Meadows

Harrison

New York

Rochester

Rockville Centre

Sleepy Hollow

Canton

Cincinnati

Portland

Allentown

Hershey

Langhorne

Greenville

Chattanooga

Knoxville

Nashville

Dallas

Fort Worth

Lubbock

San Antonio

Temple

Salt Lake City

Falls Church

Newport News

Seattle

Green Bay

Graz

Linz

Salzburg

Vienna

Wein

Santiago

Vitacura

Bogotá

Medellín

Næstved

Odense C

Bordeaux

Brest

Dijon

Lyon

Nancy

Cork

Dubin

Galway

Beersheba

Haifa

Jerusalem

Petah Tikva

Ramat Gan

Tel Aviv

Tel Litwinsky

Monterrey

Oaxaca City

Toluca

Amsterdam

Maastricht

Nijmegen

Braga

Lisbon

Porto

San Juan

Linköping

Uppsala

Bellinzona

Geneva

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Incyte Corporation

INDUSTRY